Victoria Perkins1, Kathleen Moore2, Sara Vesely3, Koji Matsuo4, Sayedamin Mostofizadeh4, Travis T Sims5, Jayanthi Lea5, Dominique Barnes6, Sixia Chen3, Matthew Carlson5, Lynda Roman4, Bradley J Monk6, Laura L Holman7. 1. Section of Gynecologic Oncology, Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. Electronic address: perkinsvb@gmail.com. 2. Section of Gynecologic Oncology, Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. 3. Department of Biostatistics and Epidemiology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. 4. Division of Gynecologic Oncology, The University of Southern California, Los Angeles, CA, USA. 5. Division of Gynecologic Oncology, The University of Texas Southwestern Medical Center, Dallas, TX, USA. 6. Arizona Oncology (US Oncology Network), Division of Gynecologic Oncology, University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ, USA. 7. Section of Gynecologic Oncology, Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. Electronic address: Laura-L-Holman@ouhsc.edu.
Abstract
OBJECTIVES: Chemotherapy is the standard treatment in stage IVB cervical cancer (CC). However, given that many women have a significant pelvic disease burden, whole pelvic radiation (WPR) in addition to chemotherapy for primary treatment may have utility. The aim of this study was to compare the overall survival (OS) and complication rates between women who received both WPR and chemotherapy (CT) versus CT alone in the management of stage IVB CC. METHODS: A multi-institutional, IRB-approved, retrospective review of patients (pts) with stage IVB CC, diagnosed between 2005 and 2015, was performed. Descriptive statistics of the demographic, oncologic, and treatment characteristics were performed. OS was estimated using the Kaplan Meier method. RESULTS: A total of 126 pts met inclusion criteria. Thirty one patients elected for hospice care at diagnosis and were excluded from further analysis. In the remaining population, median age was 53 yrs. The majority (72%) had squamous cell carcinoma and 82% had FIGO grade 2 or 3 tumors. Thirty four patients (35.8%) received WPR in addition to CT as a part of planned primary therapy and 64.2% (n = 61) received CT alone, with 88.2% and 80.3% receiving a cisplatin-based chemotherapy regimen, respectively. The OS was significantly longer in the WPR with CT group (41.6 vs 17.6 mo, p < 0.01). The rates of ureteral obstruction, vaginal bleeding, pelvic infection, pelvic pain, and fistula were not significantly different between the 2 groups (all p > 0.05). CONCLUSION: This study found WPR in addition to CT gives a significant OS benefit. Further study is warranted to determine which subgroups may benefit the most from this novel treatment strategy.
OBJECTIVES: Chemotherapy is the standard treatment in stage IVB cervical cancer (CC). However, given that many women have a significant pelvic disease burden, whole pelvic radiation (WPR) in addition to chemotherapy for primary treatment may have utility. The aim of this study was to compare the overall survival (OS) and complication rates between women who received both WPR and chemotherapy (CT) versus CT alone in the management of stage IVB CC. METHODS: A multi-institutional, IRB-approved, retrospective review of patients (pts) with stage IVB CC, diagnosed between 2005 and 2015, was performed. Descriptive statistics of the demographic, oncologic, and treatment characteristics were performed. OS was estimated using the Kaplan Meier method. RESULTS: A total of 126 pts met inclusion criteria. Thirty one patients elected for hospice care at diagnosis and were excluded from further analysis. In the remaining population, median age was 53 yrs. The majority (72%) had squamous cell carcinoma and 82% had FIGO grade 2 or 3 tumors. Thirty four patients (35.8%) received WPR in addition to CT as a part of planned primary therapy and 64.2% (n = 61) received CT alone, with 88.2% and 80.3% receiving a cisplatin-based chemotherapy regimen, respectively. The OS was significantly longer in the WPR with CT group (41.6 vs 17.6 mo, p < 0.01). The rates of ureteral obstruction, vaginal bleeding, pelvic infection, pelvic pain, and fistula were not significantly different between the 2 groups (all p > 0.05). CONCLUSION: This study found WPR in addition to CT gives a significant OS benefit. Further study is warranted to determine which subgroups may benefit the most from this novel treatment strategy.
Authors: Dana M Chase; Helen Q Huang; Lari Wenzel; David Cella; Richard McQuellon; Harry J Long; David H Moore; Bradley J Monk Journal: Gynecol Oncol Date: 2012-02-01 Impact factor: 5.482
Authors: Israel Zighelboim; Nicholas P Taylor; Matthew A Powell; Randall K Gibb; Janet S Rader; David G Mutch; Perry W Grigsby Journal: Radiat Med Date: 2006-11-24
Authors: Yuefeng Wang; Michael Farmer; Enrique W Izaguirre; David L Schwartz; Bradley Somer; Todd Tillmanns; Matthew T Ballo Journal: JAMA Oncol Date: 2018-09-01 Impact factor: 31.777
Authors: Krishnansu S Tewari; Michael W Sill; Richard T Penson; Helen Huang; Lois M Ramondetta; Lisa M Landrum; Ana Oaknin; Thomas J Reid; Mario M Leitao; Helen E Michael; Philip J DiSaia; Larry J Copeland; William T Creasman; Frederick B Stehman; Mark F Brady; Robert A Burger; J Tate Thigpen; Michael J Birrer; Steven E Waggoner; David H Moore; Katherine Y Look; Wui-Jin Koh; Bradley J Monk Journal: Lancet Date: 2017-07-27 Impact factor: 79.321
Authors: Mehmet Rıfat Goklu; Kerem Doga Seckin; Cihan Togrul; Yasemin Goklu; Ali Emre Tahaoglu; Murat Oz; Ibrahim Egemen Ertas Journal: Asian Pac J Cancer Prev Date: 2015
Authors: Sriram Venigalla; David M Guttmann; Zachary D Horne; Ruben Carmona; Jacob E Shabason; Sushil Beriwal Journal: Pract Radiat Oncol Date: 2018-05-26
Authors: Yevgeniya J Ioffe; Leslie Stewart Massad; Matthew A Powell; Andrea R Hagemann; David G Mutch; Premal H Thaker; Julie K Schwarz; Perry W Grigsby Journal: Gynecol Obstet Invest Date: 2017-04-08 Impact factor: 2.031